Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Receivables: 2012-2024

Historic Change in Receivables for Adma Biologics (ADMA) over the last 10 years, with Dec 2024 value amounting to $22.6 million.

  • Adma Biologics' Change in Receivables rose 39.55% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.5 million, marking a year-over-year increase of 365.08%. This contributed to the annual value of $22.6 million for FY2024, which is 89.48% up from last year.
  • Latest data reveals that Adma Biologics reported Change in Receivables of $22.6 million as of FY2024, which was up 89.48% from $11.9 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Change in Receivables ranged from a high of $22.6 million in FY2024 and a low of -$13.1 million during FY2022.
  • Over the past 3 years, Adma Biologics' median Change in Receivables value was $11.9 million (recorded in 2023), while the average stood at $7.1 million.
  • As far as peak fluctuations go, Adma Biologics' Change in Receivables slumped by 185.22% in 2022, and later soared by 191.16% in 2023.
  • Over the past 5 years, Adma Biologics' Change in Receivables (Yearly) stood at $9.8 million in 2020, then spiked by 57.05% to $15.3 million in 2021, then tumbled by 185.22% to -$13.1 million in 2022, then skyrocketed by 191.16% to $11.9 million in 2023, then spiked by 89.48% to $22.6 million in 2024.